middle.news
ReNerve gets FDA clarity for NervAlign nerve guide
9:28am on Wednesday 14th of October, 2026 AEDT
•
Medical Technology
Read Story
ReNerve gets FDA clarity for NervAlign nerve guide
9:28am on Wednesday 14th of October, 2026 AEDT
Key Points
FDA supports ReNerve’s proposed preclinical evaluation model
Additional control groups required for the study design
Biochemical and biophysical testing expectations outlined
Final testing plan and submission package remain in preparation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Renerve (ASX:RNV)
OPEN ARTICLE